Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRTPC02: Neoadjuvant Low-dose Radiotherapy and Chemoimmunotherapy in Resectable Locally Advanced HNSCC
NCT05343325Phase 2Active, not recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pathological Complete Response Rate. Started Mar 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05343325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343325.